Milestone Scientific Reports Q2 2025 Financial Results with $1.5M Net Loss

Milestone Scientific Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $1.5 million, compared to a net income of $223,638 in the same period of 2024. For the six months ending June 30, 2025, the company recorded a net loss of $3.5 million, up from a loss of $1.2 million in the prior year. Revenue for the second quarter increased to $2.3 million, a 25% rise from $1.9 million in the same quarter of 2024. For the first half of 2025, total revenue reached $4.6 million, compared to $4.1 million in the previous year, indicating a 11% increase.

The company's financial performance reflects a significant increase in product sales, particularly in the dental segment, which generated $2.3 million in the second quarter, up from $1.8 million a year earlier. The medical segment also saw growth, with sales rising to $32,100 from $19,000. However, the overall increase in revenue was offset by higher operating expenses, which totaled $3.1 million for the quarter, compared to $3.2 million in the previous year. The increase in expenses was attributed to higher costs in quality control, royalties, professional fees, and travel.

Milestone Scientific has made strategic moves to enhance its market position, including the launch of an e-commerce platform in January 2023, which accounted for 53% of net product sales in the second quarter of 2025. The company is also focusing on expanding its global footprint, particularly in the medical device sector, where it aims to increase adoption of its CompuFlo Epidural Computer Controlled Anesthesia System. The recent receipt of a chronology-specific CPT code from the American Medical Association is expected to facilitate reimbursement for procedures using this technology, potentially accelerating its market penetration.

Operationally, Milestone Scientific reported a decrease in its cash reserves, with cash and cash equivalents dropping to approximately $1.3 million as of June 30, 2025, down from $3.3 million at the end of 2024. The company has also experienced a significant increase in accounts payable, which rose to $1.5 million from $1.0 million. The company’s total liabilities increased to $4.7 million, compared to $4.0 million at the end of 2024. These financial pressures have raised concerns about the company's ability to continue as a going concern, prompting management to seek additional funding through equity or debt financing.

Looking ahead, Milestone Scientific aims to generate positive cash flows by increasing revenue from its dental and medical device segments while reducing operating expenses. However, the company acknowledges the challenges it faces, including the need for additional capital to support its operations and the potential impact of market conditions on its business strategy. The management remains focused on achieving profitability and expanding its product offerings in both the dental and medical markets.